IDXX stock hit a 52-week high after beating earnings expectations and raising 2025 guidance.

IDEXX Laboratories (IDXX) surged to a 52-week high of $733.52 on November 3, 2025, after reporting third-quarter earnings of $3.40 per share—exceeding the $3.14 consensus—and $1.105 billion in revenue, up 13.3% year-over-year. The company raised its 2025 earnings guidance to $12.81–$13.01 per share and revenue forecast to $4.27–$4.30 billion, citing strong performance across its Companion Animal Group, livestock and dairy, and water testing segments. Analysts responded with mixed but generally positive ratings, including upgrades from Stifel and Morgan Stanley, while the stock’s market cap reached $58.41 billion and it outperformed key moving averages.